Macrogenics (MGNX) Total Non-Current Liabilities (2012 - 2026)

Macrogenics (MGNX) reported Total Non-Current Liabilities of $195.9 million for Q1 2026, up 36.57% year-over-year from $143.5 million in Q1 2025, and down 2.13% quarter-over-quarter from $200.2 million in Q4 2025.

Macrogenics (MGNX) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends

Macrogenics (MGNX) has 14 years of Total Non-Current Liabilities data on file, last reported at $195.9 million in Q1 2026.

  • Total Non-Current Liabilities for Q1 2026 came in at $195.9 million, up 36.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $195.9 million (up 36.57% YoY), and the FY2025 annual result was $200.2 million, up 39.39% from the prior year.
  • Total Non-Current Liabilities eased to $195.9 million in Q1 2026 per MGNX's latest filing, from $200.2 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $234.0 million in Q1 2023 and troughed at $72.1 million in Q3 2022.
  • A 5-year average of $150.0 million and a median of $143.6 million in 2024 frame the typical range for Total Non-Current Liabilities.
  • The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities jumped 151.66% in 2023, then slumped 39.36% in 2024.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $138.2 million in 2022, then advanced by 5.32% to $145.5 million in 2023, then slipped by 1.32% to $143.6 million in 2024, then soared by 39.39% to $200.2 million in 2025, then retreated by 2.13% to $195.9 million in 2026.
  • Business Quant data shows MGNX's Total Non-Current Liabilities at $195.9 million in Q1 2026, $200.2 million in Q4 2025, and $202.4 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - 42,980.09
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - 11.03 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 95.20 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - 644,700.00
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 5.87 Bn
9 Abivax 91.96 Bn 91.96 Bn - 64.76 Mn
10 Macrogenics 260.14 Mn 193.63 Mn - 195.95 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 195.95 Mn
Dec 31, 2025 200.20 Mn
Sep 30, 2025 202.43 Mn
Jun 30, 2025 197.13 Mn
Mar 31, 2025 143.48 Mn
Dec 31, 2024 143.63 Mn
Sep 30, 2024 144.17 Mn
Jun 30, 2024 143.06 Mn
Mar 31, 2024 141.87 Mn
Dec 31, 2023 145.55 Mn
Sep 30, 2023 145.73 Mn
Jun 30, 2023 133.85 Mn
Mar 31, 2023 233.97 Mn
Dec 31, 2022 138.20 Mn
Sep 30, 2022 72.13 Mn
Jun 30, 2022 75.30 Mn
Mar 31, 2022 92.97 Mn
Dec 31, 2021 95.37 Mn
Sep 30, 2021 100.46 Mn
Jun 30, 2021 106.61 Mn